Literature DB >> 2913802

Pseudotumor cerebri induced by danazol.

L M Hamed1, J S Glaser, N J Schatz, T H Perez.   

Abstract

Intracranial hypertension with papilledema occurred in two patients receiving danazol therapy for either cyclic neutropenia or immune hemolytic anemia. Results of clinical, laboratory, and neuroradiologic studies showed no apparent cause for the condition in Case 1 and the papilledema resolved one month after discontinuing danazol. Carotid angiography in Case 2 demonstrated cerebral venous sinus thrombosis; the papilledema showed gradual improvement after cessation of danazol. An additional seven cases of pseudotumor cerebri presumed secondary to danazol therapy have been reported to the Food and Drug Administration. The papilledema resolved in all seven cases soon after discontinuing danazol. A drug-induced complication should be suspected, and alternative therapy sought, in patients who develop intracranial hypertension associated with administration of danazol.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913802     DOI: 10.1016/0002-9394(89)90206-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

Review 1.  Pseudotumor cerebri.

Authors:  Pietro Spennato; Claudio Ruggiero; Raffaele Stefano Parlato; Maria Consiglio Buonocore; Antonio Varone; Emilio Cianciulli; Giuseppe Cinalli
Journal:  Childs Nerv Syst       Date:  2010-08-19       Impact factor: 1.475

2.  Pseudotumour cerebri and carpal tunnel syndrome associated with danazol therapy.

Authors:  U Schmitz; C Honisch; S Zierz
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

3.  Reversible bilateral optic disc swelling in a renal patient treated with nitrofurantoin.

Authors:  Edward Pringle; Henrietta Ho; Eoin O'Sullivan; Charles Soper
Journal:  NDT Plus       Date:  2008-05-06

4.  Cyclosporine-A-Induced Intracranial Thrombotic Complications: Systematic Review and Cases Report.

Authors:  Si-Ying Song; Zhong-Ao Wang; Yu-Chuan Ding; Xun-Ming Ji; Ran Meng
Journal:  Front Neurol       Date:  2021-02-11       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.